<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35296219</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1743-2928</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>27</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Redox report : communications in free radical research</Title>
          <ISOAbbreviation>Redox Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.</ArticleTitle>
        <Pagination>
          <StartPage>79</StartPage>
          <EndPage>84</EndPage>
          <MedlinePgn>79-84</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13510002.2022.2051964</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Uric acid and edaravone might exert a neuroprotective effect in amyotrophic lateral sclerosis (ALS) by reducing oxidative stress. We analyzed whether the treatment effect of edaravone is pronounced in patients whose uric acid level increased after the treatment with edaravone.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Forty patients with ALS who underwent treatment with edaravone were included. Baseline uric acid level and the rate of decline in uric acid after edaravone treatment were recorded. The rate of change of ALS functional rating scale-revised (ΔALSFRS-R/month) was calculated based on baseline ALSFRS-R score and ALSFRS-R score 6-24 weeks after the treatment.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The serum uric acid levels decreased after treatment in 26 (65%) patients and increased in 12 (30%) patients. The ΔALSFRS-R/month was significantly faster in patients whose uric acid decreased (median 1.5 [Q1-Q3, 0.7-3.1]) than in patients whose uric acid increased (0.2 [0-1.0], <i>p</i> = 0.021). A high baseline uric acid level and low rate of decline in uric acid was associated with slower disease progression after adjusting for age, initial symptoms, and riluzole administration (<i>p</i> = 0.030 and <i>p</i> = 0.041, respectively).</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">High baseline values and low rate of decline in uric acid may predict slow disease progression in ALS patients treated with edaravone.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Hee Jo</ForeName>
            <Initials>HJ</Initials>
            <Identifier Source="ORCID">0000-0002-9482-9244</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shin</LastName>
            <ForeName>Ha Young</ForeName>
            <Initials>HY</Initials>
            <Identifier Source="ORCID">0000-0002-4408-8265</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Young-Chul</ForeName>
            <Initials>YC</Initials>
            <Identifier Source="ORCID">0000-0001-5525-6861</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Seung Min</ForeName>
            <Initials>SM</Initials>
            <Identifier Source="ORCID">0000-0002-4384-9640</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Seung Woo</ForeName>
            <Initials>SW</Initials>
            <Identifier Source="ORCID">0000-0002-5621-0811</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Redox Rep</MedlineTA>
        <NlmUniqueID>9511366</NlmUniqueID>
        <ISSNLinking>1351-0002</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>268B43MJ25</RegistryNumber>
          <NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S798V6YJRP</RegistryNumber>
          <NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014527" MajorTopicYN="Y">Uric Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ALS</Keyword>
        <Keyword MajorTopicYN="N">Uric acid</Keyword>
        <Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword>
        <Keyword MajorTopicYN="N">edaravone</Keyword>
        <Keyword MajorTopicYN="N">motor neuron</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">prognosis</Keyword>
        <Keyword MajorTopicYN="N">radical scavenger</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35296219</ArticleId>
        <ArticleId IdType="pmc">PMC8933037</ArticleId>
        <ArticleId IdType="doi">10.1080/13510002.2022.2051964</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barber SC, Mead RJ, Shaw PJ.. 
Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1051–1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16713195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Wei QQ, Chen Y, et al. . 
Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):53–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30784318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paganoni S, Zhang M, Quiroz Zarate A, et al. . 
Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012 Sep;259(9):1923–1928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4441749</ArticleId>
            <ArticleId IdType="pubmed">22323210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keizman D, Ish-Shalom M, Berliner S, et al. . 
Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?
J Neurol Sci. 2009 Oct 15;285(1-2):95–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19552925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham A, Drory VE.. 
Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014 Jun;261(6):1133–1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24699859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda K, Hirayama T, Takazawa T, et al. . 
Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501–1508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22728481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh SI, Baek S, Park JS, et al. . 
Prognostic role of serum levels of uric acid in amyotrophic lateral sclerosis. J Clin Neurol. 2015 Oct;11(4):376–382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4596112</ArticleId>
            <ArticleId IdType="pubmed">26424237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Reilly ÉJ, Liu D, Johns DR, et al. . 
Serum urate at trial entry and ALS progression in EMPOWER. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017.  2017/01/02;18(1-2):120–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5531275</ArticleId>
            <ArticleId IdType="pubmed">27677562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothstein JD.
Edaravone: A new drug approved for ALS. Cell. 2017 Nov 2;171(4):725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29100067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujisawa A, Yamamoto Y.. 
Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016 May;21(3):98–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6837651</ArticleId>
            <ArticleId IdType="pubmed">26196041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto Y.
Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. J Clin Biochem Nutr. 2017 Jan;60(1):49–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5281530</ArticleId>
            <ArticleId IdType="pubmed">28163382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohta Y, Yamashita T, Nomura E, et al. . 
Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. J Neurol Sci. 2020 Aug 15;415:116906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32446009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brooks BR, Miller RG, Swash M, et al. . 
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293–299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11464847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe K, Itoyama Y, Sobue G, et al. . 
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610–617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4266079</ArticleId>
            <ArticleId IdType="pubmed">25286015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cedarbaum JM, Stambler N, Malta E, et al. . 
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10540002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohgi H, Abe T, Yamazaki K, et al. . 
Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999 Jul;46(1):129–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10401792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith RG, Henry YK, Mattson MP, et al. . 
Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1998 Oct;44(4):696–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9778272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ihara Y, Nobukuni K, Takata H, et al. . 
Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res. 2005 Jan;27(1):105–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15829169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikawa M, Okazawa H, Tsujikawa T, et al. . 
Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology. 2015 May 19;84(20):2033–2039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25904686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nikolic-Kokic A, Stevic Z, Blagojevic D, et al. . 
Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients. Clin Chem Lab Med. 2006;44(5):589–593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16681429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cova E, Bongioanni P, Cereda C, et al. . 
Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int. 2010 Apr;56(5):687–693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20152873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Zhang Q, Ke Y, et al. . 
Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis. Sci Rep. 2018 Jan 18;8(1):1100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5773600</ArticleId>
            <ArticleId IdType="pubmed">29348425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshino H, Kimura A.. 
Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006 Dec;7(4):241–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17127563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagase M, Yamamoto Y, Miyazaki Y, et al. . 
Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016 May;21(3):104–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6837462</ArticleId>
            <ArticleId IdType="pubmed">26191780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boillée S, Vande Velde C, Cleveland DW.. 
ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006 Oct 5;52(1):39–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17015226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abe K, Aoki M, Tsuji S, et al. . 
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017 Jul;16(7):505–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28522181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shefner J, Heiman-Patterson T, Pioro EP, et al. . 
Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of study 19 (MCI186-19). Muscle Nerve. 2020 Feb;61(2):218–221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7004197</ArticleId>
            <ArticleId IdType="pubmed">31621933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiò A, Logroscino G, Hardiman O, et al. . 
Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3515205</ArticleId>
            <ArticleId IdType="pubmed">19922118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka K, Ogata S, Tanaka H, et al. . 
The relationship between body mass index and uric acid: a study on Japanese adult twins. Environ Health Prev Med. 2015 Sep;20(5):347–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4550610</ArticleId>
            <ArticleId IdType="pubmed">26037073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao X, Chen L, Xu H, et al. . 
The association between serum uric acid and bone mineral density in older adults. Int J Endocrinol. 2020;2020:3082318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7341403</ArticleId>
            <ArticleId IdType="pubmed">32676109</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
